Related Experiment Video
Updated: May 11, 2026
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Intrapleural hemorrhage due to alteplase use in a 6-year-old boy with pleural effusion
Mohamed A Hendaus1, Ahmad Abushahin
1Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.
Insights
Intrapleural alteplase, a fibrinolytic drug, can cause rare but serious intrapleural hemorrhage in children with complicated parapneumonic effusions. Healthcare providers must monitor for this potentially life-threatening side effect.
Area of Science:
- Pulmonology
- Pediatric Critical Care
- Pharmacology
Background:
- Intrapleural fibrinolytics are widely used for complicated pleural effusions and empyema.
- Alteplase is a fibrinolytic agent used in managing pleural effusions.
- Bleeding complications are known but rarely detailed, especially severe outcomes.
Observation:
- A case report details a 6-year-old male with complicated parapneumonic effusion treated with intrapleural alteplase.
- The patient experienced intrapleural hemorrhage requiring blood transfusion post-treatment.
- Literature search revealed limited data on bleeding complications of intrapleural fibrinolytics.
Findings:
- Intrapleural hemorrhage is a rare but significant adverse event associated with alteplase use.
- Existing literature primarily focuses on the efficacy of intrapleural fibrinolytics, with less emphasis on bleeding risks.
- The safety profile of alteplase in pediatric patients with pleural effusions requires further investigation.
Implications:
- Healthcare providers should maintain a high index of suspicion for intrapleural hemorrhage following alteplase administration.
- This case highlights the need for increased vigilance regarding potentially life-threatening bleeding complications in pediatric patients.
- Further research is crucial to fully elucidate the safety and efficacy of intrapleural fibrinolytics, particularly in pediatric populations.
Background:
Intrapleural fibrinolytics have been used successfully worldwide for the management of complicated pleural effusions and empyema. Bleeding complications are usually mentioned as rare side effects, but there is no clear information in the literature addressing the alarming outcome that might result following the use of alteplase as a fibrinolytic in the management of complicated parapneumonic effusions. We present a rare, if not unique, case of intrapleural hemorrhage requiring transfusion after alteplase use as a fibrinolytic in a 6-year-old male with complicated parapneumonic effusion.
Methods:
A SEARCH OF THE PUBMED DATABASE WAS CARRIED OUT, USING A COMBINATION OF THE FOLLOWING TERMS: alteplase, fibrinolytic, intrapleural hemorrhage, and side effects.
Results:
The majority of studies found in the search concentrated on the efficacy of intrapleural fibrinolytics in the management of pleural effusion, but very few of the reports addressed the bleeding complications which may be caused by the treatment.
Conclusion:
Although intrapleural and systemic hemorrhage are rare side effects of intrapleural fibrinolytic use, the health care provider must be watchful for these potentially life-threatening complications. Further studies are needed to understand not only the efficacy of fibrinolytics but also their safety, especially in children.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:25Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...
01:26Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.